Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
AHA 2026
ASUNDEXIAN
Outcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial of FXIA Inhibition with asundexian in participants with non-cardioembolics stroke of transient ischemic attack by non-laboratory Framingham Risk Score Category
Date/Time:
Saturday, November, 7 | 2026/1:45 PM – 2:45 PM (Central)
Session:
Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
Type:
Digital Moderated Poster
Presenting Author:
Makul Sharma
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
